Clinical Trial Update: A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study of GNC-038 Injection in adults with relapsed or refractory Non-Hodgkin lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• GNC-038 Injection (GNC-038)

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Non-hodgkin's Lymphoma | Phase 1, Phase 2 | Status: RECRUITING